OBESITY ASSOCIATED WITH DEFECTS IN LEPTIN-MELANOCORTIN PATHWAY

Clinical trials for OBESITY ASSOCIATED WITH DEFECTS IN LEPTIN-MELANOCORTIN PATHWAY explained in plain language.

Never miss a new study

Get alerted when new OBESITY ASSOCIATED WITH DEFECTS IN LEPTIN-MELANOCORTIN PATHWAY trials appear

Sign up with your email to follow new studies for OBESITY ASSOCIATED WITH DEFECTS IN LEPTIN-MELANOCORTIN PATHWAY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Hope for lasting weight control in rare genetic obesity

Disease control ENROLLING_BY_INVITATION

This study continues testing setmelanotide, a medication for rare genetic obesity conditions, to check its long-term safety. It includes patients aged 2 and older who benefited from the drug in earlier trials. The main goal is to monitor side effects over an extended treatment pe…

Matched conditions: OBESITY ASSOCIATED WITH DEFECTS IN LEPTIN-MELANOCORTIN PATHWAY

Phase: PHASE3 • Sponsor: Rhythm Pharmaceuticals, Inc. • Aim: Disease control

Last updated Mar 30, 2026 14:31 UTC

OBESITY ASSOCIATED WITH DEFECTS IN LEPTIN-MELANOCORTIN PATHWAY

Get alerted when new OBESITY ASSOCIATED WITH DEFECTS IN LEPTIN-MELANOCORTIN PATHWAY trials appear

Hope for lasting weight control in rare genetic obesity